Check out your Company Bowl for anonymous work chats.
Omada for Cholesterol is virtual care designed for everyday cholesterol management that adapts to how people actually live. Unlike programs that treat cholesterol as a standalone stat or a one-time intervention, we approach cholesterol management with ongoing support that’s part of overall cardiometabolic care. This reflects how cardiovascular risk actually develops: gradually, across daily decisions, and often alongside other cardiometabolic conditions. Read more about our product innovation: https://lnkd.in/eqjgs-ir
We're excited to share $OMDA's Q4 and EOY 2025 results, marking our first quarter of GAAP net income profitability: 📈 Revenue up 53% YOY to $260M for the full year 👥 Member growth of 55% YOY to 886K members at year end 📊 GAAP Net Income of $5M in Q4 📉Significantly narrowed Net Loss for 2025 💫 Positive Adjusted EBITDA in 2025 We’re proud to also announce a new GLP-1 offering for employers - as roughly more than half employers don’t cover GLP-1 medications. GLP‑1 Flex Pay gives employers a flexible option to connect employees with anti-obesity medication, virtual care, and lifestyle support. The need for this support is clear, with members touting how the support of Omada’s program impacts their daily lives: "The Omada program in collaboration with my doctor and the use of GLP‑1 meds has been life changing. I learned real skills needed to lose weight and be healthy for a lifetime…” Read more about our Q4 and end-of-year performance, including a reconciliation of GAAP to non-GAAP measures: https://buff.ly/c4tqmV6
Not sure which GLP-1 path is right for your population? Hear from Omada Health CEO Sean Duffy to explain GLP-1 Flex Care, a new support option that employers can offer directly to their workforce. This launch gives employers a more flexible way to support safe, effective obesity care. This offering is part of Omada’s broader cardiometabolic strategy, which includes Omada for Cholesterol and the launch of prescribing capabilities starting with GLP-1s and other obesity medications, so employers can choose the pathways that best fit their benefit design. Curious to know more? Read about GLP-1 Flex Care: https://lnkd.in/gxpi6V67
For large employers, covering GLP-1s is no longer a “yes/no” decision. These medications are reshaping health benefits at a scale we haven’t seen in decades—and large employers are defining what happens next. In this month’s edition of Proof Points, Britt Buntman, Omada’s VP of GLP‑1 & Cardiometabolic Health, unpacks why a simple “yes/no” coverage decision is no longer viable when you’re responsible for thousands of lives and a finite benefits budget.
International Women’s Day is a moment to recognize the women who move our teams, our industry, and our communities forward. To all the women of Omada—and to our customers, partners, and members—thank you for the expertise, leadership, and perspectives you bring every day. #InternationalWomensDay #IWD2026
Employers are under pressure to offer GLP-1s but need options that won’t blow up budgets. Omada’s new GLP-1 Flex Care adds a path for employers to support obesity care while keeping medication spend outside the plan. With GLP-1 Flex Care, eligible members receive clinical evaluation, lab ordering, prescribing of FDA-approved GLP-1 medications, and ongoing virtual care and lifestyle support. Members then purchase medications independently through reputable cash-pay channels, helping employers limit direct exposure to medication costs. Why should benefits leaders care? GLP-1 demand is growing, and this model adds room to maneuver as pricing and coverage policies continue to shift—without forcing a choice between access and affordability. Want a GLP-1 path that fits your current benefit design? Learn more in our GLP-1 Flex Care announcement: https://lnkd.in/gxpi6V67
✨ Everyone loves a plot twist, even research scientists! New research from Omada Insights Lab found that members who stopped taking their GLP-1s earlier than planned still experienced notable weight loss of 13.1% over 12 months, outperforming typical real-world outcomes of 6.8%. Learn more about the findings here: https://buff.ly/2XCUJ92
Did you guess correctly? In some studies, GLP-1 patients lose up to 45% of lean mass as a proportion of total weight lost. Why should individuals and organizations care? Our latest whitepaper breaks down how muscle loss can undermine long-term GLP-1 weight loss outcomes. Read it now. https://buff.ly/vuaFYNp
If you answered resistance training, you are correct. We’ll also accept “strength training.” Research shows that minimal-dose approaches to resistance training are very effective for stimulating muscle. Why is this such an important part of maintaining weight loss for GLP-1 users? To find out, read our latest whitepaper now. https://buff.ly/vuaFYNp
Heart Health is a year-round priority but this month we take a moment to celebrate #AmericanHeartMonth Heart disease is the leading cause of death in the U.S., with someone suffering from a heart attack approximately every 40 seconds. ✨The good news: many of these events are linked to modifiable risk factors. At Omada, our cardiometabolic specialists focus on the everyday drivers of cardiovascular risk: high blood pressure, high cholesterol, diabetes, and obesity. ❤️ By helping members understand and take action,we see meaningful improvements in cardiometabolic risk profiles over time. ❤️ Learn more about our cardiovascular care: https://buff.ly/HlMFDkE
